Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers

Travel Medicine and Infectious Disease

Volumn 4, Issue 6, 2006, Pages 313-318

  Clarke, Paul D ^a   Adams, Phillip ^a   Ibáñez, Rubén ^b   Herzog, Christian ^b  

^a MASTA Travel Health Centre   (United Kingdom)

^b Berna Biotech AG   (Switzerland)

Author keywords

Hepatitis A; Tolerability; Travellers; Virosome adjuvanted vaccine

Indexed keywords

ALUMINUM; HEPATITIS A VACCINE; MONODOSE; VIROSOME VACCINE;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG FORMULATION; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FREQUENCY ANALYSIS; HEADACHE; HEPATITIS A; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; POSTAL MAIL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; SKIN REDNESS; TRAVEL; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GREAT BRITAIN; HEPATITIS A VACCINES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PAIN MEASUREMENT; TRAVEL; VACCINES, INACTIVATED; VACCINES, VIROSOME;

EID: 33750627530     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2006.01.001     Document Type: Article

References (19)

1. Koff R.S. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 10 Suppl. 1 (1992) S15-S17
2. Holzer B.R., and Egger M. Hepatitis A vaccine. Curr Opin Infect Dis 8 (1995) 186-190
3. Van Damme P., and Bell B. Hepatitis A: how to match prevention strategies to changing epidemiology. Vaccine 19 (2001) 999-1002
4. Fiore A, Bell B. Prevention of specific infectious diseases: hepatitis, viral, type A. In: Kozarsky PE, Arquin PM, Navin AW, editors. Health information for international travel 2005-2006. Centers for Disease Control and Prevention; 2005 [cited August 15, 2005]. Available from: http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=dis&obj=hav.htm
5. WHO. Hepatitis A vaccines-WHO position paper. Wkly Epidemiol Rec 75 (2000) 38-44
6. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 (1992) 453-457
7. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271 (1994) 1328-1334
8. Mayorga Perez O., Herzog C., Zellmeyer M., Loaisiga A., Frösner G., and Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 188 (2003) 671-677
9. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60 (2000) 1-7
10. Fan P.C., Chang M.H., Lee P.I., Safary A., and Lee C.Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 16 (1998) 232-235
11. Glück R., Mischler R., Brantschen S., Just M., Althaus B., and Cryz Jr. S.J. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90 (1992) 2491-2495
12. Moser C., Metcalfe I.C., and Viret J.F. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2 (2003) 189-196
13. Bovier P.A., Farinelli T., and Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 23 (2005) 2424-2429
14. Holzer B.R., Hatz C., Schmidt-Sissolak D., Glück R., Althaus B., and Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14 (1996) 982-986
15. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48 (No. RR-12):1-37.
16. Linglof T., van Hattum J., Kaplan K.M., Corrigan J., Duval I., Jensen E., et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. Vaccine 19 (2001) 3968-3971
17. Hornick R., Tucker R., Kaplan K.M., Eves K.A., Banerjee D., Jensen E., et al. Randomized study of a flexible booster, dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. Vaccine 19 (2001) 4727-4731
18. Westblom T.U., Gudipati S., DeRousse C., Midkiff B.R., and Belshe R.B. Safety and immunigenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 169 (1994) 996-1001
19. Van Herck K., Van Damme P., Castelli F., Zuckerman J., Nothdurft H., Dahlgren A.L., et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 11 (2004) 3-8